Weili Jia

Weili Jia

Auto-generated profile, based on publicly available information

Weili Jia

Department of Neurology, Beijing Tiantan Hospital, Capital Medical University, Beijing, China

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
17 November 2023 in Journal of Cerebral Blood Flow & Metabolism
Verified
Journal Article
Closed access
WJWei-Li Jia
Wei-Li Jia
YJYing-Yu Jiang
Ying-Yu Jiang
YJYong Jiang
Yong Jiang
XMXia Meng
Xia Meng
HLHao Li
Hao Li
ZLZi-Xiao Li
Zi-Xiao Li
The modified Rankin Scale change score (ΔmRS) is useful for evaluating acute poststroke functional improvement or deterioration. We investigated the relationship between multiple biomarkers and ΔmRS by analyzing data on 6931 patients with acute ischemic stroke (average age 62.3 ± 11.3 years, 2174 (31.4%) female) enrolled from the Third China National Stroke Registry (CNSR-III) and 15 available biomarkers. Worse outcomes at 3 months were defined as ΔmRS3m-discharge ≥1 (ΔmRS3m-discharge = mRS3m-mRSdischarge). Adjusted odds ratios (aORs) and their 95% confidence intervals (CIs) were calculated from logistic regression models. At 3-months poststroke, 1026 (14.8%) patients experienced worse outcomes. The highest quartiles of white blood cells (WBCs) (aOR [95%CI],1.37 [1.12–1.66]), high-sensitivity C-reactive protein (hs-CRP) (1.37 [1.12–1.67]), interleukin-6 (IL-6) (1.43 [1.16–1.76]), interleukin-1 receptor antagonist (IL-1Ra) (1.46 [1.20–1.78]) and YKL-40 (1.31 [1.06–1.63]) were associated with an increased risk of worse outcomes at 3 months. Results remained stable except for YKL-40 when simultaneously adding multiple biomarkers to the basic traditional-risk-factor model. Similar results were observed at 6 and 12 months after stroke. This study indicated that WBCs, hs-CRP, IL-6, IL-1Ra, and YKL-40 were significantly associated with worse outcomes in acute ischemic stroke patients, and all inflammatory biomarkers except YKL-40 were independent predictors of worse outcomes at 3 months.

7 November 2023 in Journal of the American Heart Association
Verified
Journal Article
Open access
CWChunjuan Wang
Chunjuan Wang
WJWeili Jia
Weili Jia
JJJing Jing
Jing Jing
XMXia Meng
Xia Meng
AWAnxin Wang
Anxin Wang
FIfor the CHANCE‐2 Investigators
for the CHANCE‐2 Investigators
Background: This study aimed to investigate the efficacy and safety of ticagrelor–aspirin versus clopidogrel–aspirin in Chinese patients by the presence and clinical presentation of intracranial artery stenosis (ICAS) using randomized trial data from the CHANCE‐2 (Clopidogrel in High‐Risk Patients With Acute Nondisabling Cerebrovascular Events‐II) trial. Methods and Results: A total of 6412 patients with minor stroke or transient ischemic attack who carried CYP2C19 loss‐of‐function alleles were randomized to either the ticagrelor–aspirin or clopidogrel–aspirin group. Patients without imaging of the intracranial artery were excluded from the nonprespecified subgroup analysis of CHANCE‐2. All patients included were classified into the following groups: without ICAS, symptomatic ICAS, or asymptomatic ICAS. The primary efficacy outcome was new strokes within 90 days. There were 5893 patients (median age, 64.8 years; 33.9% women) included, and 172 (4.9%), 171 (10.5%), and 57 (7.7%) cases of new strokes occurred within 90 days in the without ICAS, with symptomatic ICAS, and with asymptomatic ICAS groups, respectively. Ticagrelor–aspirin was associated with reduced risk of new stroke in patients without ICAS (62 [3.5%] versus 110 [6.3%]; hazard ratio [HR], 0.57 [95% CI, 0.41–0.78]) but not in those with symptomatic ICAS (HR, 0.77 [95% CI, 0.56–1.05]) or in those with asymptomatic ICAS (HR, 0.77 [95% CI, 0.43–1.38]) compared with clopidogrel–aspirin ( P for interaction=0.14). There were no significant differences in the proportion of severe or moderate bleeding events among different ICAS groups. Conclusions: Patients without ICAS received a significantly greater benefit from ticagrelor–aspirin than clopidogrel–aspirin after minor ischemic stroke or transient ischemic attack, and there was no statistically significant difference between treatments in patients with symptomatic ICAS or asymptomatic ICAS. Registration: URL: https://www.clinicaltrials.gov ; Unique identifier: NCT04078737.

17 October 2023 in Brain Research
Verified
Journal Article
Closed access
WJWeili Jia
Weili Jia
YZYijun Zhou
Yijun Zhou
LZLijun Zuo
Lijun Zuo
ZLZiyang Liu
Ziyang Liu
ZPZi-Xiao Li PhD
Zi-Xiao Li PhD

24 May 2024 in Stroke and Vascular Neurology
Verified
Journal Article
Open access
QJQian Jia
Qian Jia
PLPeng Lei
Peng Lei
LSLi Sun
Li Sun
WJWei Li Jia
Wei Li Jia
YPYuesong Pan
Yuesong Pan
YWYongjun Wang
Yongjun Wang
Background: The incidence of vascular cognitive impairment (VCI) is high in patients suffering from ischaemic stroke or transient ischaemic attack (TIA) or with vascular risk factors. Effective prevention strategies for VCI remain limited. Anaemia or low haemoglobin was found as an independent risk factor for adverse outcomes after acute stroke. Anaemia or low haemoglobin was possibly associated with an increased risk of poststroke cognitive impairment. Whether supplement of ferrous iron to correct anaemia reduces the risk of VCI and improves adverse outcomes in patients with ischaemic cerebrovascular disease remains uncertain. Aim: We aim to introduce the design and rationale of the safety and efficacy of Ferrous iron on the prevention of Vascular cOgnitive impaiRment in patients with cerebral Infarction or TIA (FAVORITE) trial. Design: FAVORITE is a randomised, placebo-controlled, double-blind, multicentre trial that compares supplement of ferrous iron with placebo for recent minor stroke/TIA patients complicated with mild anaemia or iron deficiency: Ferrous succinate sustained-release tablet 0.2 g (corresponding to 70 mg of elemental iron) once daily after or during breakfast for 12 weeks or placebo with much the same colour, smell and size as ferrous iron once daily during or after breakfast for 12 weeks. All paticipants will be followed within the next year. Study outcomes: The primary effective outcome is the incidence of VCI at 3 months after randomisation and the primary safety outcome includes any gastrointestinal adverse event during 3 months. Discussion: The FAVORITE trial will clarify whether supplement of ferrous iron to correct low haemoglobin reduces the risk of VCI in patients with recent ischaemic stroke or TIA complicated with mild anaemia or iron deficiency compared with placebo. Trial registration number: NCT03891277

16 October 2026 in Stroke and Vascular Neurology
Verified
Journal Article
Open access
WJWeili Jia
Weili Jia
XZXinyang Zhang
Xinyang Zhang
XLXiaohong Li
Xiaohong Li
JZJiayi Zhao
Jiayi Zhao
XZXiaoying Zhao
Xiaoying Zhao
ZPZi-Xiao Li PhD
Zi-Xiao Li PhD